監管
LYNKUET (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer
Bayer announced that Health Canada issued a Notice of Compliance expanding the indication for LYNKUET (elinzanetant) to the treatment of moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy related to breast cancer, making it the first approved treatment option in Canada for that patient population. The expansion builds on Health Canada's July 2025 authorization of LYNKUET for moderate to severe VMS associated with menopause and was supported by Bayer's OASIS-4 study. LYNKUET is a once-daily oral, non-hormonal dual neurokinin-targeted therapy antagonizing both NK-1 and NK-3 receptors.
大盤 開啟原文 ↗